Cohance Lifesciences promoters Berhyanda Limited and Jusmiral Holdings Limited have indirectly encumbered 57.49% of their shares. This significant pledging, effective June 16, 2026, is to secure financing from international banks, creating a key watch point for investors.

Cohance Lifesciences Promoters Encumber 57.49% Stake

Promoters of Cohance Lifesciences have pledged 219,930,170 shares, representing 57.49% of the total equity.

Reader Takeaway: Promoters securing financing via significant share pledging; investors should monitor loan covenant compliance.

What just happened

Berhyanda Limited and Jusmiral Holdings Limited, promoter entities of Cohance Lifesciences, have indirectly encumbered 219,930,170 equity shares. This represents 57.49% of the company's total share capital.

The encumbrance, effective from June 16, 2026, stems from facility agreements signed on June 11, 2026, with several international financial institutions, including Barclays Bank Plc, Deutsche Bank AG, BNP Paribas, MUFG Bank, and Standard Chartered Bank.

Why this matters

High levels of promoter pledging are a key concern for investors. It signifies that a substantial portion of the promoter's ownership is tied to debt obligations. Any stress in the promoters' financial health or inability to meet loan covenants could potentially lead to margin calls or forced selling of these shares, impacting the stock price.

The backstory

The two promoter entities, Berhyanda Limited holding 33.34% and Jusmiral Holdings Limited holding 24.15% of the total share capital, have collectively pledged their entire stakes.

What changes now

While this is an indirect encumbrance, meaning the borrowing entities' shareholders have not directly pledged the shares, the effective control and beneficial interest tied to these shares are now linked to the repayment of the secured loans.

Risks to watch

The primary risk for investors is the high degree of pledging. The market will closely watch the company's and promoters' ability to service the debt associated with these encumbrances. A default or breach of covenants could have significant repercussions.

Peer comparison

Information regarding peer company promoter pledging levels is not provided in the filing. However, a promoter stake of over 50% being encumbered is generally considered substantial and warrants investor attention.

Context metrics (time-bound)

• Total Encumbered Shares: 219,930,170
• Total Encumbered (%): 57.49%
• Effective Date: June 16, 2026
• Facility Agreement Date: June 11, 2026

What to track next

Investors should monitor future financial disclosures from Cohance Lifesciences for any updates regarding these loan facilities and the status of the encumbrances. Compliance with loan covenants and the overall financial health of the promoter group will be critical indicators.